Langrick A F
Curr Med Res Opin. 1984;9(5):290-5. doi: 10.1185/03007998409109594.
Sixty-nine patients were entered into a randomized, single-blind, parallel group study. Patients had a history of moderate to severe seasonal allergic rhinitis and all patients commenced treatment before the start of the pollen season. Treatment was with either flunisolide or beclomethasone dipropionate, both being administered as 2 sprays to each nostril twice daily for 7 weeks. Assessments of signs and symptoms of hay fever were made at admission and after 3 and 7-weeks' treatment. Patients were asked to keep a daily record of the severity of their symptoms. The overall effect of treatment was evaluated by both the patient and physician. Side-effects were elicited by indirect questioning. Sixty patients completed the study. Four patients from the flunisolide group and 2 from the beclomethasone group were lost to follow-up. Two further patients withdrew from the flunisolide group and 1 from the beclomethasone group. Analysis of results did not reveal any statistically significant differences between the treatments. Minor side-effects were reported by 1 patient from each treatment group. Both treatments proved to be effective in the treatment of hay fever and were equally well tolerated.
69名患者进入了一项随机、单盲、平行组研究。患者有中度至重度季节性过敏性鼻炎病史，且所有患者在花粉季节开始前就开始治疗。治疗药物为氟尼缩松或二丙酸倍氯米松，均为每侧鼻孔每日2喷，每日2次，持续7周。在入院时以及治疗3周和7周后对花粉热的体征和症状进行评估。要求患者每天记录其症状的严重程度。治疗的总体效果由患者和医生共同评估。通过间接询问了解副作用情况。60名患者完成了研究。氟尼缩松组有4名患者和倍氯米松组有2名患者失访。氟尼缩松组另有2名患者退出，倍氯米松组有1名患者退出。结果分析未显示两种治疗之间有任何统计学上的显著差异。每个治疗组均有1名患者报告了轻微副作用。两种治疗方法在治疗花粉热方面均被证明有效，且耐受性相当。
